In this week’s episode of #AskDrDurie, IMF Chairman Dr. Brian Durie looks at the factors of myeloma that affect the choice of treatment, including the type of myeloma and any chromosome abnormalities, as well as genetic testing done on the patient.

Previous Post
Bringing Next Generation Flow (NGF) Cytometry to Japan
Next Post
Is it possible to boost the immune system for myeloma patients?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.